Business, energy, technology, markets and global industry news from Business News Today

Nona Biosciences

PharmaDeviceNews Nona Biosciences
Harbour BioMed’s antibody discovery platforms and global biopharma partnerships are supporting revenue growth and a seventh consecutive profitable half-year, although the company’s full interim results will determine the durability of its earnings momentum. Representative image.
Pharma & Biotech

Harbour BioMed’s revenue is climbing, but one profit number complicates the growth story

Harbour BioMed expects up to $67 million interim profit as antibody deals lift revenue, but margin trends will shape the next investor debate.

Read More
Representative image: Nona Biosciences and Lonza are developing a single-domain antibody platform designed to improve blood-brain barrier crossing and support next-generation central nervous system drug delivery.
Pharma & Biotech

Why the Nona Biosciences and Lonza alliance matters for brain-penetrant biologics

Nona Biosciences and Lonza are building a single-domain antibody platform to cross the blood-brain barrier. Explore the clinical and licensing stakes.

Read More